Scilex Holding Company Operating Cash Flow
Scilex Holding Company (SCLX) reported Operating Cash Flow of -$7.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Scilex Holding Company net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.74M, a 195.56% decline year-over-year.
- Scilex Holding Company net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.11M, a 118.43% decline year-over-year.
- Scilex Holding Company net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$17.47M, a 789.46% decline year-over-year.
- Scilex Holding Company net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $8.23M, a 60.96% increase year-over-year.
- Scilex Holding Company net cash provided by (used in) operating activities for fiscal 2025 was $3.82M, a 80.28% decline from fiscal 2024.
- Scilex Holding Company net cash provided by (used in) operating activities for fiscal 2024 was $19.35M.
- Scilex Holding Company net cash provided by (used in) operating activities for fiscal 2023 was -$20.71M.
- Scilex Holding Company net cash provided by (used in) operating activities for fiscal 2022 was -$21.26M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 7 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 10 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$7.84M 10-Q · filed 2026-08-14 | -$25.32M derived: sum of 3 quarters · filed 2026-08-14 | -$17.09M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2026-03-31 | -$1.11M 10-Q · filed 2026-05-20 | -$18.58M derived: sum of 2 quarters · filed 2026-05-20 | -$10.35M derived: sum of 3 quarters · filed 2026-05-20 | -$3.30M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-12-31 | -$17.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$9.24M derived: sum of 2 quarters · filed 2026-04-10 | -$2.19M derived: sum of 3 quarters · filed 2026-08-14 | $3.82M 10-K · filed 2026-04-10 | ||||||
| 2025-09-30 | $8.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $15.28M derived: sum of 2 quarters · filed 2026-08-14 | $21.29M 10-Q · filed 2025-11-14 | $23.82M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-06-30 | $7.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $13.06M 10-Q · filed 2026-08-14 | $15.59M derived: sum of 3 quarters · filed 2026-08-14 | $20.70M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-03-31 | $6.01M 10-Q · filed 2026-05-20 | $8.54M derived: sum of 2 quarters · filed 2026-05-20 | $13.65M derived: sum of 3 quarters · filed 2026-05-20 | $15.96M derived: sum of 4 quarters · filed 2026-05-20 | ||||||
| 2024-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $7.65M derived: sum of 2 quarters · filed 2026-04-10 | $9.96M derived: sum of 3 quarters · filed 2026-04-10 | $19.35M 10-K · filed 2026-04-10 | ||||||
| 2024-09-30 | $5.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $7.42M derived: sum of 2 quarters · filed 2025-11-14 | $16.82M 10-Q · filed 2025-11-14 | $11.43M derived: sum of 4 quarters · filed 2025-11-14 | ||||||
| 2024-06-30 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $11.70M 10-Q · filed 2025-08-13 | $6.31M derived: sum of 3 quarters · filed 2025-08-13 | $12.21M derived: sum of 4 quarters · filed 2025-08-13 | ||||||
| 2024-03-31 | $9.39M 10-Q · filed 2025-05-14 | $4.00M derived: sum of 2 quarters · filed 2025-05-14 | $9.90M derived: sum of 3 quarters · filed 2025-05-14 | -$3.57M derived: sum of 4 quarters · filed 2025-05-14 | ||||||
| 2023-12-31 | -$5.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $510.00K derived: sum of 2 quarters · filed 2025-03-31 | -$12.96M derived: sum of 3 quarters · filed 2025-03-31 | -$20.71M 10-K · filed 2025-03-31 | ||||||
| 2023-09-30 | $5.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | -$7.57M derived: sum of 2 quarters · filed 2025-01-17 | -$15.32M 10-Q · filed 2025-01-17 | -$16.04M derived: sum of 4 quarters · filed 2025-01-17 | ||||||
| 2023-06-30 | -$13.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$21.22M 10-Q · filed 2024-08-13 | -$21.94M derived: sum of 3 quarters · filed 2024-08-13 | -$19.41M derived: sum of 4 quarters · filed 2024-08-13 | ||||||
| 2023-03-31 | -$7.74M 10-Q · filed 2024-05-13 | -$8.47M derived: sum of 2 quarters · filed 2024-05-13 | -$5.94M derived: sum of 3 quarters · filed 2024-05-13 | -$18.27M derived: sum of 4 quarters · filed 2024-05-13 | ||||||
| 2022-12-31 | -$725.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.81M derived: sum of 2 quarters · filed 2024-03-12 | -$10.53M derived: sum of 3 quarters · filed 2024-03-12 | -$21.26M 10-K · filed 2024-03-12 | ||||||
| 2022-09-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$9.80M derived: sum of 2 quarters · filed 2023-11-14 | -$20.53M 10-Q · filed 2023-11-14 | -$1.94M 10-Q · filed 2022-11-04 | -$48.50M derived: sum of 4 quarters · filed 2024-03-12 | |||||
| 2022-06-30 | -$12.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$23.07M 10-Q · filed 2023-08-11 | -$1.62M 10-Q · filed 2022-08-12 | -$51.04M derived: sum of 3 quarters · filed 2024-03-12 | -$51.18M derived: sum of 4 quarters · filed 2024-03-12 | |||||
| 2022-03-31 | -$10.73M 10-Q · filed 2023-05-12 | -$880.48K 10-Q · filed 2022-05-16 | -$38.70M derived: sum of 2 quarters · filed 2024-03-12 | -$38.84M derived: sum of 3 quarters · filed 2024-03-12 | -$39.40M derived: sum of 4 quarters · filed 2024-03-12 | |||||
| 2021-12-31 | -$27.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$28.11M derived: sum of 2 quarters · filed 2024-03-12 | -$28.66M derived: sum of 3 quarters · filed 2024-03-12 | -$28.66M 10-K · filed 2024-03-12 | -$801.33K 10-K · filed 2022-02-24 | |||||
| 2021-09-30 | -$141.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$693.61K derived: sum of 2 quarters · filed 2022-11-04 | -$693.61K 10-Q · filed 2022-11-04 | |||||||
| 2021-06-30 | -$551.63K 10-Q/A · filed 2021-08-24 | -$551.63K 10-Q · filed 2022-08-12 | ||||||||
| 2021-03-31 | -$494.33K 10-Q · filed 2022-05-16 | |||||||||
| 2020-12-31 | -$1.28K 10-K · filed 2022-02-24 | -$31.46M 10-K · filed 2023-03-07 | ||||||||
| 2020-09-30 | -$856.00 10-Q/A · filed 2021-12-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |